Interferon (IFN)-γ-inducible protein-10:: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection

被引:181
|
作者
Romero, Ana I.
Lagging, Martin
Westin, Johan
Dhillon, Amar P.
Dustin, Lynn B.
Pawlotsky, Jean-Michel
Neumann, Avidan U.
Ferrari, Carlo
Missale, Gabriele
Haagmans, Bart L.
Schalm, Solko W.
Zeuzem, Stefan
Negro, Francesco
Verheij-Hart, Elke
Hellstrand, Kristoffer
机构
[1] Univ Gothenburg, Dept Virol, SE-41346 Gothenburg, Sweden
[2] Univ Gothenburg, Dept Infect Dis, SE-41346 Gothenburg, Sweden
[3] Royal Free Hosp, Dept Histopathol, London NW3 2QG, England
[4] Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA
[5] Univ Paris 12, Hop Henri Mondor, F-94010 Creteil, France
[6] Bar Ilan Univ, Ramat Gan, Israel
[7] Azienda Osped Parma, Parma, Italy
[8] Erasmus MC, Dept Virol, Rotterdam, Netherlands
[9] Univ Hosp Rotterdam Dijkzigt, Rotterdam, Netherlands
[10] Saarland Univ Hosp, Homburg, Germany
[11] Univ Hosp Geneva, Geneva, Switzerland
来源
JOURNAL OF INFECTIOUS DISEASES | 2006年 / 194卷 / 07期
关键词
D O I
10.1086/507307
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4. Methods. Plasma IP-10 was monitored before, during, and after treatment with pegylated IFN-alpha 2a and ribavirin in 265 HCV-infected patients. Results. In univariate analyses, a low baseline IP-10 level was significantly associated with low baseline viral load, rapid viral response (RVR), a sustained viral response (SVR), body mass index <= 25 kg/m(2), and less-pronounced fibrosis, inflammation, and steatosis (for HCV genotypes other than 3). When the results of the univariate analyses were included in multivariate analyses, a low plasma IP-10 level, low baseline viral load, and genotype 2 or 3 infection were independent predictors of an RVR and SVR. IP-10 levels decreased 6 weeks into treatment and remained low in patients with an SVR. By contrast, plasma levels of IP-10 rebounded in patients who had detectable HCV RNA after the completion of treatment. Using cutoff IP-10 levels of 150 and 600 pg/mL for predicting an SVR in patients infected with HCV genotype 1 yielded a specificity and sensitivity of 81% and 95%, respectively. Conclusion. Baseline IP-10 levels are predictive of the response to HCV treatment.
引用
收藏
页码:895 / 903
页数:9
相关论文
共 50 条
  • [1] Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C
    Aghemo, Alessio
    Rumi, Maria Grazia
    Colombo, Massimo
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (08) : 925 - 935
  • [2] Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children
    Pawlowska, Malgorzata
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 343 - 348
  • [3] Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians
    Gong, Lu-Lu
    Zhao, Bin-Bin
    Fan, Wen-Feng
    Gong, Lu-Yu
    Chen, Cai-Feng
    Liu, Jing-Jun
    Lu, Xuan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (07): : 8367 - 8375
  • [4] Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan
    Hsu, Ching-Sheng
    Liu, Chun-Jen
    Lai, Ming-Yang
    Chen, Pei-Jer
    Kao, Jia-Horng
    Chen, Ding-Shinn
    [J]. INTERVIROLOGY, 2007, 50 (04) : 310 - 315
  • [5] Retinopathy with pegylated interferon alpha 2a and ribavirin during a chronic viral hepatitis C
    Ngatcha, G.
    Rouibaa, F.
    Majdouli, S.
    Arouah, A.
    Feqhi, A.
    Oubaaz, A.
    [J]. JOURNAL AFRICAIN D HEPATO-GASTROENTEROLOGIE, 2013, 7 (01): : 53 - 56
  • [6] HCV-specific production of IL-10 and IFN-gamma-inducible protein-10 (IP-10) levels predict treatment response to pegylated interferon and ribavirin in children with chronic hepatitis C infection
    Carey, Ivana
    Mytilinaiou, Maria
    Hussain, Munther
    Bansal, Sanjay
    Subramaniam, Pushpa
    Horner, Mary
    Longhi, Maria Serena
    Meda, Francesca
    Mieli-Vergani, Giorgina
    Vergani, Diego
    [J]. HEPATOLOGY, 2007, 46 (04) : 279A - 279A
  • [7] Early viral kinetics on treatment with pegylated interferon-α-2a in chronic hepatitis C virus genotype 1 infection
    Jessner, W
    Stauber, R
    Hackl, F
    Datz, C
    Watkins-Riedel, T
    Hofer, H
    Gangl, A
    Kessler, H
    Ferenci, P
    [J]. JOURNAL OF VIRAL HEPATITIS, 2003, 10 (01) : 37 - 42
  • [8] Hemolytic anemia during pegylated IFN-α2b plus ribavirin treatment for chronic hepatitis C:: Ribavirin is not always the culprit
    Gentile, I
    Viola, C
    Reynaud, L
    Borrelli, F
    Cerini, R
    Ciampi, R
    Piazza, M
    Borgia, G
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2005, 25 (05): : 283 - 285
  • [9] Combination of interferon (IFN) α-2a and ribavirin therapy in chronic hepatitis C infection (HCV) after ineffective interferon α-2a monotherapy
    Perdita, W
    Ramadori, G
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A1261 - A1261
  • [10] The clinical significance of interferon inducible protein-10 in chronic hepatitis C patients with genotype I undergoing pegylated interferon and ribavirin therapy
    Kim, Chung Ho
    Kim, Ji Hoon
    Jong, Young Kul
    Kim, Jeong Han
    Choi, Jong Hwan
    Hong, Seong Kweon
    Ju, Moon Kyung
    Lee, Beom Jae
    Yim, Hyung Joon
    Yeon, Jong Eun
    Park, Jong-Jae
    Kim, Jae Seon
    Bak, Young Tae
    Byun, Kwan Soo
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A42 - A42